Clinical Trials
58
Active:0
Completed:43
Trial Phases
3 Phases
Phase 1:22
Phase 2:20
Phase 3:16
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (58 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (37.9%)Phase 2
20 (34.5%)Phase 3
16 (27.6%)An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
- First Posted Date
- 2016-06-23
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02811159
- Locations
- 🇺🇸
KO Clinical Research, LLC, Fort Lauderdale, Florida, United States
🇺🇸Atlanta Women's Research Institute, Inc., Atlanta, Georgia, United States
🇺🇸WR-Mount Vernon Clinical Research, LLC, Sandy Springs, Georgia, United States
A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene
Phase 2
Completed
- Conditions
- Acquired Hypogonadotropic HypogonadismObesity
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2019-06-27
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02651688
Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2019-06-25
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT02323646
A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids
- First Posted Date
- 2014-11-26
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02301897
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸MomDoc Women's Health Research, Scottsdale, Arizona, United States
🇺🇸KO Clinical Research, LLC, Fort Lauderdale, Florida, United States
An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration
- First Posted Date
- 2014-10-24
- Last Posted Date
- 2015-03-12
- Lead Sponsor
- Repros Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02274181
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
No news found